APA (7th ed.) Citation

R, E., M, K., H, K., M, M., D, F., Y, T., . . . M, T. (2019). Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PloS one, 14(7), e0220570. https://doi.org/10.1371/journal.pone.0220570

Chicago Style (17th ed.) Citation

R, Edahiro, et al. "Clinical Outcomes in Non-small Cell Lung Cancer Patients with an Ultra-high Expression of Programmed Death Ligand-1 Treated Using Pembrolizumab as a First-line Therapy: A Retrospective Multicenter Cohort Study in Japan." PloS One 14, no. 7 (2019): e0220570. https://doi.org/10.1371/journal.pone.0220570.

MLA (9th ed.) Citation

R, Edahiro, et al. "Clinical Outcomes in Non-small Cell Lung Cancer Patients with an Ultra-high Expression of Programmed Death Ligand-1 Treated Using Pembrolizumab as a First-line Therapy: A Retrospective Multicenter Cohort Study in Japan." PloS One, vol. 14, no. 7, 2019, p. e0220570, https://doi.org/10.1371/journal.pone.0220570.